AMRI and Cystic Fibrosis Foundation Therapeutics, Inc. (CFFT) entered a four-year research collaboration aimed at identifying novel treatments that address the core defect in cystic fibrosis. Under the collaboration, CFFT will commit as much as $23.7 million, if specific clinical development milestones are met. Under the agreement, AMRI will screen its natural-product based libraries to find compounds that improve the function of the defective protein in CF, known as the cystic fibrosis tran...